medical news
.... The phase 1 trial in Geneva is due for completion in the middle of 2015.
Assuming a successful outcome, the company plans to conduct
multi-centre clinical phase IIa trials in Europe in 2015-2017. The goal
is to establish the cancer-specific treatment efficacy and safety of
MVX-ONCO-1 in larger lung, ovarian and pancreatic cancer
patient populations. The company is conducting a new financing round
with existing and new private investors to support these clinical
programs.......
About MVX-ONCO-1
MaxiVAX' novel Immuno-Oncology therapy is based on triggering the
patient's own natural immune response mechanism via an innovative and
proprietary technology in order to eliminate the cancer cells.
MVX-ONCO-1 has been classified as an Advanced Therapeutic Medicinal
Product by the European Medicines Agency.
MVX-ONCO-1 consists of a two-component system:
1) Vaccine: administered by sub-cutaneous injection, this uses the
patient's own irradiated cancer cells as vaccine antigens, with a key
benefit of using the entire set of tumor antigens from the patient's cell
2) Immune boosting agent: an immune boosting agent (GM-CSF:
granulocyte-macrophage colony stimulating factor) is continuously
delivered via encapsulated cells. The capsule, a small hollow fibre, is
placed underneath the skin at the same site as the vaccine injection.
The vaccine and the immune-booster are both being administered 6 times over a period of 8 weeks in this first clinical trial.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.